<abstract id="Abs1"><sec><title>Background</title><p id="Par1">Duloxetine, Etoricoxib and opioid are of the commonly administered
    drugs in Lumbar laminectomy. The aim of this study is to assess the effect
    of perioperative use of Duloxetine in combination with Etoricoxib on
    postoperative pain and opioid requirements.</p></sec><sec><title>Methods</title><p id="Par2">One hundred twenty patients with ASA physical status were enrolled
    with age between 18 and 70&#x000a0;years. Patients were divided randomly
    into four groups of 30 patients: group P received placebo, group E received
    etoricoxib 120&#x000a0;mg, group D received duloxetine 60&#x000a0;mg and
    group D/E received duloxetine 60&#x000a0;mg capsules and etoricoxib
    120&#x000a0;mg; 1 h before surgery and 24&#x000a0;h after.</p></sec><sec><title>Results</title><p id="Par3">Neither Duloxetine nor etoricoxib individually had effect on pain
    with movement, while their combination revealed a significant reduction in
    pain scores over the entire postoperative period at rest and on movement.
    Etoricoxib showed a significant decrease in pain at all times at rest when
    compared with group P, while it showed significant pain decrease only at 0,
    2 and 4&#x000a0;h when compared with group D. On the other hand duloxetine
    alone showed significant decrease in pain at rest at 24&#x000a0;h and
    48&#x000a0;h when compared with group P. ConcerningMorphine requirement
    after 24&#x000a0;h.; it wassignificantly lower in the D/E group in
    comparison with groups P, E and D. It should be noted also that there was a
    significant decrease morphine requirement in both groups E and D.</p></sec><sec><title>Conclusion</title><p id="Par4">The perioperative administration of the combination of etoricoxib
    and duloxetine improved analgesia and reduced opioid consumption without
    significant side effects.</p></sec><sec><title>Trial registration</title><p id="Par5"><ext-link ext-link-type="uri"
        xlink:href="http://www.isrctn.com/ISRCTN48329522?q=&#x00026;filters=conditionCategory:Surgery,trialStatus:Completed,trialStatus:Completed&#x00026;sort=&#x00026;offset=1&#x00026;totalResults=731&#x00026;page=1&#x00026;pageSize=10&#x00026;searchType=basic-search">
    ISRCTN48329522</ext-link>. 17 June 2017</p></sec></abstract><sec id="Sec5"><title>Results</title><p id="Par36">From November 1, 2015 to March 1, 2017, 131 consecutive patients who met the
inclusion criteria were allocated for the study (Fig.&#x000a0;<xref rid="Fig1"
    ref-type="fig">1</xref>). Eleven patients refused to participate. Therefore, 120
patients were randomized and included in the study. Characteristics of patients and surgical
procedures for each group (Table&#x000a0;<xref rid="Tab1" ref-type="table">
    1</xref>) showed no significant differences between the groups.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow diagram for participant</p></caption><graphic xlink:href="12871_2017_450_Fig1_HTML" id="MO1" /></fig><table-wrap
    id="Tab1"><label>Table 1</label><caption><p>Characteristics of patients and surgical procedures in the four groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Group<break />Variable</th><th>Group (P)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group (E)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group (D)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group (D/E)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Age (years)</td><td>46.50&#x02009;&#x000b1;&#x02009;8.74</td><td>45.26&#x02009;&#x000b1;&#x02009;7.50</td><td>48.36&#x02009;&#x000b1;&#x02009;9.80</td><td>47.50&#x02009;&#x000b1;&#x02009;10.14</td><td>0.455</td></tr><tr><td>Male/Female (n)</td><td>15/15</td><td>17/13</td><td>18/12</td><td>16/14</td><td>0.471</td></tr><tr><td>Weight (kg)</td><td>81.23&#x02009;&#x000b1;&#x02009;13.24</td><td>82.53&#x02009;&#x000b1;&#x02009;12.90</td><td>80.60&#x02009;&#x000b1;&#x02009;13.37</td><td>78.83&#x02009;&#x000b1;&#x02009;16.78</td><td>0.794</td></tr><tr><td>Height (cm)</td><td>167.46&#x02009;&#x000b1;&#x02009;8.50</td><td>165.53&#x02009;&#x000b1;&#x02009;7.71</td><td>165.40&#x02009;&#x000b1;&#x02009;8.21</td><td>165.00&#x02009;&#x000b1;&#x02009;9.63</td><td>0.478</td></tr><tr><td colspan="6">ASA (n)</td></tr><tr><td>&#x02003;I</td><td>18</td><td>18</td><td>17</td><td>15</td><td>0.36</td></tr><tr><td>&#x02003;II</td><td>7</td><td>6</td><td>9</td><td>10</td><td>0.42</td></tr><tr><td>&#x02003;III</td><td>5</td><td>6</td><td>4</td><td>5</td><td>0.23</td></tr><tr><td>&#x02003;Duration of surgery (min)</td><td>109.9&#x02009;&#x000b1;&#x02009;10.8</td><td>115.7&#x02009;&#x000b1;&#x02009;9.8</td><td>113.2&#x02009;&#x000b1;&#x02009;13.7</td><td>117.8&#x02009;&#x000b1;&#x02009;9.7</td><td>0.65</td></tr></tbody></table><table-wrap-foot><p>Data are presented as Mean&#x02009;&#x000b1;&#x02009;SD or number (n)</p><p>Placebo group (P), Etoricoxib group (E), Duloxetine group (D),
Duloxetine/Etoricoxib group (D/E). Data were analyzed using ANOVA test with post hoc
            test (Bonferroni) and chi square test</p></table-wrap-foot></table-wrap></p><sec id="Sec6"><title>The morphine requirement</title><p id="Par37">The time to first rescue analgesic was significantly prolonged in (D/E)when
    compared with group D, group E and group P.There was a significant prolongation when
    groups E and D were compared with group P respectively with no significant difference
    between group E and group D (Fig.&#x000a0;<xref
        rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Time to morphine administration after surgery in the four groups as
                Mean(SD). Placebo group (P), etoricoxib (E), Duloxetine (D),
    Duloxetine/etoricoxib (D/E). a: when compared with P group. b: when compared
                with E group. c: when compared with D group. d: when compared with E/D group</p></caption><graphic xlink:href="12871_2017_450_Fig2_HTML" id="MO2" /></fig></p><p id="Par38">The morphine requirement at 24&#x000a0;h was statistically different
    between the four groups.</p><p id="Par39">. There were significantly increased morphine requirements in the P group
    compared with E, D and D/E groups and significantly increased in E and D groups
    respectively when compared with D/E group with no significant difference between group E
    and group D (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). At 48&#x000a0;h,
    total morphine requirement were still significantly increased in the P group compared
    with all groups with significant increases in both E and D groups when compared with D/E
    group with no significant difference between group E and group D (Fig.&#x000a0;<xref
        rid="Fig4" ref-type="fig">4</xref>). But it was still significantly lower in the
    three groups at 48&#x000a0;h post-surgery when compared with those required at24 h.<fig
        id="Fig3"><label>Fig. 3</label><caption><p>Morphine requirements at 24&#x000a0;h in the four groups as mean
                (SD). Placebo group (P), etoricoxib (E), Duloxetine (D),
    Duloxetine/etoricoxib
                (D/E). a: when compared with P group. b: when compared with E group. c: when
    compared with D group. d: when compared with E/D group</p></caption><graphic xlink:href="12871_2017_450_Fig3_HTML" id="MO3" /></fig><fig
        id="Fig4"><label>Fig. 4</label><caption><p>Morphine requirements at 48&#x000a0;h in the four groups as mean
                (SD). Placebo group (P), etoricoxib (E), Duloxetine (D),
    Duloxetine/etoricoxib
                (D/E). a: when compared with P group. b: when compared with E group. c: when
    compared with D group. d: when compared with E/D group</p></caption><graphic xlink:href="12871_2017_450_Fig4_HTML" id="MO4" /></fig></p></sec><sec id="Sec7"><title>The pain score</title><p id="Par40">With regard to pain scores at rest all time points, the duloxetine/etoricoxib
    (D/E) group had significantly lower pain scores when compared to placebo group P, while
    when it compared to etoricoxib group E, also when compared D/E with duloxetine group D
    (Table&#x000a0;<xref rid="Tab2"
        ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Pain scores (NRS) at rest in the four groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Group<break />Variable</th><th>Group (P)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group (E)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group (D)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group (D/E)<break />(<italic>n</italic> &#x02009;=&#x02009;30)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>At 0&#x000a0;h</td><td>5 (4-5.25)<sup>bd</sup></td><td>4 (3-4) <sup>acd</sup></td><td>4 (3-5) <sup>bd</sup></td><td>3 (3-4) <sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 2&#x000a0;h</td><td>4 (3-5)bd</td><td>3 (3-4) <sup>acd</sup></td><td>4 (3-5) <sup>bd</sup></td><td>3 (3-3)<sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 4&#x000a0;h</td><td>4 (3-5) <sup>bd</sup></td><td>3 (3-4) <sup>acd</sup></td><td>3 (3-4) <sup>bd</sup></td><td>2 (2-3)<sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 6&#x000a0;h</td><td>3 (3-4) <sup>bd</sup></td><td>3 (2-4) <sup>ad</sup></td><td>2.5 (2-3)<sup>d</sup></td><td>2 (1-3) <sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 12&#x000a0;h</td><td>3 (3-3) <sup>bd</sup></td><td>3 (2-3) <sup>ad</sup></td><td>3 (2-3)<sup>d</sup></td><td>2.5 (1-3) <sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 24&#x000a0;h</td><td>3 (2-3) <sup>bcd</sup></td><td>2(2-3) <sup>ad</sup></td><td>2.5 (2-3) <sup>ad</sup></td><td>2 (1-2)<sup>abc</sup></td><td>0.0001</td></tr><tr><td>At 48&#x000a0;h</td><td>3 (2-3) <sup>bcd</sup></td><td>2 (2-3) <sup>ad</sup></td><td>2 (2-3) <sup>ad</sup></td><td>2 (0.75-2)<sup>abc</sup></td><td>0.0001</td></tr></tbody></table><table-wrap-foot><p>Placebo group (P), Etoricoxib (E), Duloxetine (D),
                Duloxetine/Etoricoxib (D/E)</p><p>Data are presented as median (interquartile range). Data were analyzed by
    Mann&#x02013;Whitney U-test and kruksal-wallis test and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05
    is considered significant</p><p>a: when compared with P group</p><p>b: when compared with E group</p><p>c: when compared with D group</p><p>d: when compared with D/E group</p></table-wrap-foot></table-wrap></p><p id="Par41">The pain score in group E was significantly decreased at most time periods
    when compared to group P at 0, 2 and 4&#x000a0;h at rest when compared with group D. The
    pain score in group D was significantly decrease at 24 and 48&#x000a0;h compared to
    group P (Table <xref rid="Tab2" ref-type="table">2</xref> ).</p><p id="Par42">While on movement pain was significantly decreased in D/E at all times when
    compared togroup P and when it compared to group E and when it compared to group D with
    no significant difference between other groups on movement (Table&#x000a0;<xref
        rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Pain scores (NRS) on movement in the four groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Group<break />Variable</th><th>Group (P)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group (E)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group (D)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group (D/E)<break />(<italic>n</italic> &#x02009;=&#x02009;30)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>0&#x000a0;h</td><td>5 (5-6.25) <sup>d</sup></td><td>5 (5-6) <sup>d</sup></td><td>5 (5-6) <sup>d</sup></td><td>5 (4.5.25) <sup>abc</sup></td><td>0.013</td></tr><tr><td>After 2&#x000a0;h</td><td>5 (5-6) <sup>d</sup></td><td>5 (4-6) <sup>d</sup></td><td>5 (5-6) <sup>d</sup></td><td>5 (4-5) <sup>abc</sup></td><td>0.002</td></tr><tr><td>After 4&#x000a0;h</td><td>4 (4-5) <sup>d</sup></td><td>4 (4-5) <sup>d</sup></td><td>4 (4-5) <sup>d</sup></td><td>4 (3-4) <sup>abc</sup></td><td>0.019</td></tr><tr><td>After 6&#x000a0;h</td><td>4 (3-5) <sup>d</sup></td><td>4 (3-5) <sup>d</sup></td><td>4 (4-5) <sup>d</sup></td><td>4 (3-4) <sup>abc</sup></td><td>0.007</td></tr><tr><td>After 12&#x000a0;h</td><td>4 (3-5) <sup>d</sup></td><td>4 (3-4) <sup>d</sup></td><td>4 (3-4.25) <sup>d</sup></td><td>3 (3-4) <sup>abc</sup></td><td>0.030</td></tr><tr><td>After 24&#x000a0;h</td><td>4 (3-5) <sup>d</sup></td><td>4 (3-4.25) <sup>d</sup></td><td>4 (3-4) <sup>d</sup></td><td>3 (2.75-4) <sup>abc</sup></td><td>0.059</td></tr><tr><td>After 48&#x000a0;h</td><td>3.5 (3-4) <sup>d</sup></td><td>3 (3-4) <sup>d</sup></td><td>3.5 (3-4) <sup>d</sup></td><td>3 (2.75-4) <sup>abc</sup></td><td>0.049</td></tr></tbody></table><table-wrap-foot><p>Placebo group (P), Etoricoxib (E), Duloxetine (D),
                Duloxetine/Etoricoxib (D/E)</p><p>Data are presented as median (interquartile range). Data were analyzed by
    Mann&#x02013;Whitney U-test and kruksal-wallis test and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05
    is considered significant. a: when compared with P group</p><p>b: when compared with E group</p><p>c: when compared with D group</p><p>d: when compared with D/E group</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Patients&#x02019; satisfaction</title><p id="Par43">The percentage of patients&#x02019; satisfaction (excellent) shows significant
    differences between the four groups at 24&#x000a0;h (Table&#x000a0;<xref
        rid="Tab4" ref-type="table">4</xref>) with no significant differences between the
    three groups at 48&#x000a0;h.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Patient&#x02019;s satisfaction in the four groups at 24&#x000a0;h</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Group<break />Patient satisfaction</th><th>Group(P)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group(E)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group(D)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group(D/E)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>p</th></tr></thead><tbody><tr><td>ExEellent</td><td>9 (30%)</td><td>12(40%)</td><td>11(36.7%)</td><td>21 (63.3%)*</td><td>0.004</td></tr><tr><td>Good</td><td>9(30%)</td><td>10(33.3%)</td><td>9(30%)</td><td>5(23.3%)</td><td>0.237</td></tr><tr><td>Fair</td><td>8(26.7%)</td><td>5 (16.5%)</td><td>6(20%)</td><td>2(6.7%)</td><td>0.069</td></tr><tr><td>Poor</td><td>4(13.3%)</td><td>3(10%)</td><td>3(10%)</td><td>2(6.7%)</td><td>0.933</td></tr></tbody></table><table-wrap-foot><p>Data are presented as number (%). Data were analyzed using chi square.
    Placebo group (P), Etoricoxib (E), Duloxetine (D), Duloxetine/Etoricoxib (D/E). <italic>
    P</italic>&#x02009;&#x0003c;&#x02009;0.05 is considered significant</p><p>*<italic>P</italic>&#x02009;=&#x02009;0.016 when compare with P</p></table-wrap-foot></table-wrap></p><p id="Par44">The most common adverse effect expected by patients in the study was nausea
    and vomiting grades III and IV. There was a significant increase in percentage of
    patients in group P (43.3%) when compared with group D/E (16.6%) and who reported nausea
    and vomiting. All complained patients responded to i.v.ondansetron. No statistically
    significant differences were noted between groups with regard to adverse effects
    (Table&#x000a0;<xref rid="Tab5"
        ref-type="table">5</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Side effects in the four groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Group<break />Side effect</th><th>Group(P)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group(E)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group(D)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>Group(D/E)<break />(<italic>n</italic>&#x02009;=&#x02009;30)</th><th>p</th></tr></thead><tbody><tr><td>PONV (%)<break />IIII&#x00026;IV</td><td>13 (43.3%)*</td><td>7 (23.3%)</td><td>7 (23.3%)</td><td>5 (16.6%)</td><td>0.027</td></tr><tr><td>Somnolence</td><td>1 (3.3%)</td><td>1 (3.3%)</td><td>2 (6.7%)</td><td>3 (10%)</td><td>0.225</td></tr><tr><td>Pruritus</td><td>5 (16.7%)</td><td>4 (13.3%)</td><td>3 (10%)</td><td>3 (10%)</td><td>0.390</td></tr><tr><td>Dizziness</td><td>1 (3.3%)</td><td>2 (6.7%)</td><td>4 (13.3%)</td><td>3 (10%)</td><td>0.239</td></tr><tr><td>Headache</td><td>6 (20%)</td><td>3 (10%)</td><td>5 (16.7%)</td><td>4 (13.3%)</td><td>0.907</td></tr></tbody></table><table-wrap-foot><p>Data are presented as number (%). Data were analyzed using chi square test
    and fisher&#x02019;s exact test. Placebo group (P), Etoricoxib (E), Duloxetine (D),
    Duloxetine/Etoricoxib (D/E). <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 is
    considered significant. *<italic>P</italic>&#x02009;=&#x02009;0.024 when compare P and
    D/E</p></table-wrap-foot></table-wrap></p></sec></sec>